A PHASE II, OPEN LABEL, SINGLE-ARM, MULTI-CENTRE STUDY TO EVALUATE THE SAFETY
AND EFFICACY OF OSIMERTINIB WITH AMIVANTAMAB AS FIRST-LINE TREATMENT IN
PARTICIPANTS WITH EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION POSITIVE,
LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (OSTARA)
- Registry ID
- D5162C00052
- Source registry
- HEALTH_CANADA
- Status
- Pending
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- ASTRAZENECA AB
- Last update
- 2023-08-17
Conditions
- LOCALLY ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER
Related clinical trials
- A PHASE 2/3 OPEN LABEL RANDOMIZED STUDY OF TELISOTUZUMAB ADIZUTECAN COMPARED TO STANDARD OF CARE IN SUBJECTS WITH LOCALLY ADVANCED OR METASTATIC EGFR-MUTATED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER AFTER PROGRESSION ON A THIRD-GENERATION EGFR TKI - ANDROMETA-LUNG-713
- A GLOBAL, PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FIRMONERTINIB COMPARED WITH INVESTIGATOR’S CHOICE OF OSIMERTINIB OR AFATINIB AS FIRST-LINE TREATMENT IN PARTICIPANTS WHO HAVE LOCALLY ADVANCED OR METASTATIC NON-SMALLCELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR P-LOOP AND ALPHA C-HELIX COMPRESSING (PACC) UNCOMMON MUTATIONS (ALPACCA)
- A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE
EFFICACY AND SAFETY OF DIVARASIB AND PEMBROLIZUMAB
VERSUS PEMBROLIZUMAB AND PEMETREXED AND CARBOPLATIN
OR CISPLATIN IN PATIENTS WITH PREVIOUSLY UNTREATED, KRAS
G12C-MUTATED, ADVANCED OR METASTATIC NON-SQUAMOUS
NON¿SMALL CELL LUNG CANCER
- A PHASE III, RANDOMISED, OPEN-LABEL, MULTICENTRE STUDY OF DATOPOTAMAB
DERUXTECAN OR DOCETAXEL IN PREVIOUSLY TREATED TROP2-POSITIVE ADVANCED OR
METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER WITHOUT ACTIONABLE
GENOMIC ALTERATIONS (TROPION-LUNG17)
- A PHASE 1/2 OPEN-LABEL, MULTICENTER, FIRST-IN-HUMAN STUDY OF THE SAFETY,
TOLERABILITY, PHARMACOKINETICS, AND ANTITUMOR ACTIVITY OF BH-30643 IN ADULT
SUBJECTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC HARBORING EGFR
AND/OR HER2 MUTATIONS (SOLARA)
- A PHASE III, RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED, MULTICENTRE,
INTERNATIONAL STUDY OF DURVALUMAB PLUS DOMVANALIMAB (AB154) IN PARTICIPANTS
WITH LOCALLY ADVANCED (STAGE III), UNRESECTABLE NON SMALL CELL LUNG CANCER
WHOSE DISEASE HAS NOT PROGRESSED FOLLOWING DEFINITIVE PLATINUM BASED
CONCURRENT CHEMORADIATION THERAPY (PACIFIC 8)
View on source registry